Depomed, Inc. (DEPO) insider have most recently took part in a trading activity. On Dec 14, 2017 Higgins Arthur J, President and CEO bought 75,000 shares having total worth of $612,000 at the price of $8.16 per share, following the transaction a total of 111,760 shares owned by Higgins Arthur J. Before this latest buy, Higgins Arthur J purchased DEPO at 1 other times during the past twelve months, for a total investment of $148,800 at an average of $9.92 per share.
Furthermore, over the past 12 months , the stock was traded 4 times by insiders. In 3 of these trades, the insider was a seller while an employee of the company was the buyer in 1 instances.
Shares of Depomed, Inc. (DEPO) traded down 3.43% on Dec 14, 2017, hitting $8.16. 1,485,027 shares of the company’s stock traded hands. Depomed, Inc. has a 52 week low of $4.56 and a 52 week high of $26.01. The company’s market cap is $1,500 million.
Depomed, Inc. (DEPO) last announced its earnings results on Nov 7, 2017. The company reported 0.14 earnings per share (EPS) for the quarter, higher than the consensus estimate of 0.12 by $0.02. The company had revenue of $95 million for the quarter, compared to the consensus estimate of $101 million. During the same quarter in the previous year, the company posted 0.28 earnings per share. The company’s revenue for the quarter was down 14% on a year-over-year basis.
|earnings per share||0.14||0.08||0.07||0.48||0.28||0.27||0.12||0.16||0.33||0.27|
Depomed, Inc. was incorporated in the State of California on August 7, 1995. The Company is a specialty pharmaceutical company that focuses on pain and other conditions and diseases of the central nervous system. Its products line encompasses Gralise, Zipsor, Glumetza, Janumet XR, and Proquin XR, among others. The core products comprises of Gralise, a once-daily product for the management of postherpetic neuralgia, and Zipsor liquid filled capsules, a product for the treatment of mild to moderate acute pain. It also has a portfolio of royalty and milestone producing assets based on its proprietary drug delivery technologies. A part of it is Glumetza, a once-daily treatment for adults with type 2 diabetes which is licensed and commercialized in the United States. It also has license and development arrangements for Acuform gastroretentive drug delivery technology with Covidien, Ltd., Boehringer Ingelheim International GMBH, Ironwood Pharmaceuticals, Inc., Merck & Co., Inc., Janssen Pharmaceutica N.V. and Janssen Pharmaceuticals, Inc. Further, it has two product candidates in clinical development, Serada and DM-1992. The Company derives revenues from the sale of its products, and from license fees, milestones and royalties earned on license agreements, as well as collaborative arrangements.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018